Sofinnova Partners launches €165M Biovelocita II fund for early-stage science in Italy, France, UK & Denmark, backed by Amgen ...

A year after the Biosecure Act was introduced, WuXi AppTec’s US revenue growth continued to drop significantly, and the ...

Maxion Therapeutics has secured $72 million in an oversubscribed Series A raise, with Eli Lilly pitching in, to advance its ...

The Trump administration defended HHS’ rejection of drugmakers' 340B rebate models “at this time,” but suggested that the ...

Boston biotech hC Bioscience shuts down after failed hemophilia A program, CEO Leslie Williams says. Company had raised $40M ...

AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple ...

AstraZeneca reports Phase 3 success for eneboparatide in hypoparathyroidism following $1.05B Amolyt Pharma acquisition. Drug ...

Orca Bio on Monday said its T cell therapy, when used in people with certain blood cancers, reduced the risk of treatment ...

The second round of Medicare price negotiations is now underway for all 15 selected drugs with signed agreements in place ...

Incyte's povorcitinib meets endpoints in hidradenitis suppurativa trials but shows lower efficacy than expected, lagging behind UCB's Bimzelx in Phase 3 studies.

AstraZeneca to acquire EsoBiotec for $425M upfront, with $575M in potential milestones. Deal centers on platform technology ...

Curevo Vaccine raises $110M Series B for shingles vaccine trial extension, adds Moncef Slaoui as board chair and Moderna's Tal Zaks to board. Aims to compete with GSK's Shingrix.